ClinicaSpace.com
Clinical Research
News & Careers
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   
 News | News By Subject | News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Genentech (RHHBY) Takes Exelixis, Inc. (EXEL) Drug Into Phase III Melanoma Trial


1/17/2013 7:37:06 AM

Genentech Inc. is moving forward with a cancer-fighting combo that includes a drug it licensed from Exelixis Inc., giving the smaller biotech company the option to potentially co-promote the drug. Genentech, the South San Francisco-based biotech subsidiary of drug giant Roche, dosed the first patient Monday in the Phase III trial, Exelixis said in a Securities and Exchange Commission filing Wednesday. The study is evaluating already-approved Zelboraf in combination with Exelixis-discovered GDC-0973 in patients with malignant melanoma. Exelixis (NASDAQ: EXEL), also based in South San Francisco, has 12 months to exercise its option to co-promote GDC-0973 in the United States, according to the SEC filing.



 Read Article at  Related Companies  News Categories
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES